Introduction
HIV infection causes high mortality and rapid disease progression in infants. 1, 2 If untreated, more than a third of infected infants die during infancy and about half by 2 years of age. 3, 4 Although early antiretroviral therapy (ART) is life-saving, treatment duration is lifelong. ART options are scarce in resource-poor settings, and even fewer are available for infants because of formulation and pharmacokinetic limitations and the risk of resistance after exposure to drugs used to prevent mother-to-child transmission. 5 The cumulative eff ects of treatment in the growing child are worrying, with longterm pharmacovigilance data unavailable. Therefore, we postulated that compared with deferred ART, a strategy of early time-limited ART initiated close to primary infection would prevent disease progression and safely allow a subsequent period off ART, thus preserving future treatment options.
In 2007, when the median follow-up time of the CHER trial was 40 weeks (IQR 24-58), interim data showed that early ART reduced the risk of death by 75% compared with deferred ART, 2 and subsequently became the standard of care. [6] [7] [8] Here, we report the 5-year results of the completed CHER trial.
Methods

Study design and participants
Infants aged 6-12 weeks with confi rmed HIV infection test results and a percentage of CD4-positive T lymphocytes (CD4%) of 25% or higher were eligible for inclusion in the study. No previous ART was allowed, apart from treatment for prevention of mother-to-child transmission. Exclusion criteria included birthweight less than 2 kg, grade 3 or 4 laboratory abnormalities (transaminases, neutrophil count, haemoglobin, electrolytes, and creatinine), clinically signifi cant medical events, and life-threatening congenital abnormalities (appendix pp 1-2). 2 Infants were randomly assigned to one of three strategies: deferred therapy (ART-Def), early ART restricted to 40 weeks (ART-40W), or early ART restricted to 96 weeks (ART-96W). The immunological criterion for initiation of ART in ART-Def or re-initiation of continuous ART after interruption was CD4% less than 20% (later revised in February, 2007 to CD4% less than 25% or CD4 count less than 1000 cells per mm³ during infancy). 9 Corresponding clinical criteria were protocol-defi ned Centers for Disease Control and Prevention (CDC) severe stage B or stage C events, the former including oxygendependent lymphoid interstitial pneumonitis or bronchiectasis, nephropathy, and cardiomyopathy. Failure to thrive, not meeting CDC stage C criteria, recurrent pneumonia, and severe oral candidiasis were added during the trial to prompt starting and restarting of ART (see appendix pp 131-133 for defi nitions).
The fi rst 40 infants with baseline CD4% lower than 25% were randomly allocated to ART-40W or ART-96W 
Study treatment and randomisation
First-line ART was twice-daily zidovudine (240 mg/m² per dose) and lamivudine (4 mg/kg per dose), provided by GlaxoSmithKline, with lopinavir-ritonavir (300 mg/m² per dose plus 75 mg/m² per dose) until 6 months of age, 10 then 230 mg/m² per dose plus 57·5 mg/m² per dose. Second-line ART was didanosine, abacavir, and nevirapine or efavirenz. Within-class switching for tolerability and drug-specifi c toxicity was allowed. Criteria for second-line therapy, lopinavirritonavir, and second-line ART were supplied by the South African Department of Health.
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The trial statistician at the Medical Research Council Clinical Trials Unit, London, prepared the randomisation schedule stratifi ed by clinical site with permuted blocks of random sizes to balance the numbers of infants allocated to each group. The data manager at the Perinatal HIV Research Unit implemented the schedule by fax for each participant.
Procedures and follow-up
We identifi ed HIV-exposed infants from the public prevention of mother-to-child transmission programmes in the Western Cape and Gauteng provinces. We did HIV DNA PCR from 4 weeks of age when cotrimoxazole prophylaxis started. HIV infection was confi rmed by plasma HIV RNA PCR greater than 1000 copies per mL. The prevention of mother-to-child transmission regimen was single-dose nevirapine to mother and neonate in both centres. In the Western Cape, zidovudine was also given to mothers from 34 weeks' gestation and to neonates for 7 days. Breastfeeding was allowed. Infants were reviewed every 4 weeks until week 24, every 8 weeks until week 48, and then every 12 weeks. At every scheduled visit, we assessed HIV-related clinical events, full blood count with diff erential, biochemistry tests, and T-cell subsets. We used Division of AIDS criteria to grade adverse events. 12 Most infants (349/377 [93%]) also enrolled on a study assessing the eff ect of ART strategy on response to conjugated 7-valent pneumococcal and Haemophilus infl uenzae type b vaccines. 13 The primary endpoint was time to death or failure of fi rst-line ART, defi ned as CD4% decrease to less than 20% from week 24; CDC severe stage B or stage C events; 14 or regimen-limiting toxicity (more than one drug substitution within the same class, switching to a new class, or need for permanent treatment discontinuation). Virological failure, defi ned as confi rmed (repeat within 4 weeks) HIV-RNA viral load of 10 000 copies per mm³ or greater after 24 weeks on ART, was included after October, 2009, when viral load measurements became standard of care. We obtained previous viral load data retrospectively from stored specimens.
Secondary endpoints were time to starting or needing to start continuous ART; cumulative CDC severe stage B, C, or other signifi cant clinical events or death at 3·5 years; grade 3 or 4 clinical or laboratory adverse events; admissions to hospital; and viral resistance.
A composite secondary endpoint was time to death or life-threatening stage C events or HIV events associated with end-organ damage. Life-threatening stage C events were lymphoma or Kaposi's sarcoma, progressive multifocal leukoencephalopathy, or intercurrent infec tion needing treatment in an intensive care unit. HIV events with end-organ damage included unresolved HIV encephalopathy, chronic lung disease, cardio myopathy, Mean log and nephropathy. The term primary therapy refers to early time-limited ART from randomisation to treatment interruption in the early ART groups.
An independent clinical End-point Review Committee adjudicated cause of all deaths and reviewed CDC severe stage B and C events, without knowledge of CD4 values, ART status, or treatment group.
Statistical analyses
As described previously, 2 we calculated that 375 infants (125 per group), enrolled over a period of 18 months and followed up for at least 3·5 years, provided 80% power to reject the null hypothesis of no diff erence between groups in time to primary endpoint if the average hazard ratio (HR) is 0·72 for ART-40W and 0·50 for ART-96W relative to ART-Def. This calculation was based on a global log-rank test with two-sided α level of 0·05. After a protocol amendment, which raised the CD4% threshold for ART initiation in infants from below 20% to below 25% in accordance with updated WHO guidelines, 9 34 additional infants were enrolled between September, 2007, and March, 2008, to retain 80% power. By the time of the second interim analysis on June 20, 2007, the independent Data Safety and Monitoring Board had already recommended discontinuation of enrolment to the ART-Def group. Therefore, these infants were randomly assigned to the ART-40W or ART-96W groups, and contributed data only to the secondary comparison between the early time-limited ART groups.
Time-to-event methods (Kaplan-Meier plots and logrank test stratifi ed by site) compared treatment groups for time to primary endpoint and survival. We used Cox proportional hazard modelling to estimate summary HRs for death or treatment failure for ART-40W and ART-96W compared with ART-Def.
We compared the three groups for percentage of total follow-up time on ART and time from randomisation to initiation of continuous ART (estimated with Kaplan-Meier methods). For the latter comparison, follow-up in ART-Def was censored on June 20, 2007 when the Data Safety Monitoring Board recommended that all children in ART-Def should be assessed for ART initiation.
The frequency of grade 3 or 4 adverse events was compared across groups with the χ² test. Changes in CD4% and cell count over time were summarised by point estimates of mean changes from baseline, documented at each visit. Follow-up data were censored either when participants were lost to follow-up before July 1, 2011, or on that date. Loss to follow-up was defi ned as no return within 6 months of a previous study visit. All randomised comparisons were by intention to treat; p values are two-sided.
The Data Safety Monitoring Board reviewed the trial at least annually. Per protocol, the board viewed early trial termination or protocol modifi cation as proof beyond reasonable doubt of clear benefi t or harm from a randomised treatment strategy with use of the HaybittlePeto criterion, based on a diff erence of at least 3 SDs in 
Role of the funding source
Representatives from the US National Institutes of Health were part of the study team and were involved in study design, data interpretation, and writing of the report. The pharmaceutical company and departments of health from Gauteng and the Western Cape that provided study drugs had no role in the study design, analysis, or preparation of the report. The corresponding authors had full access to all study data and had fi nal responsibility for the decision to submit for publication.
Results
Of 591 HIV-infected infants screened, 411 had CD4% of 25% or higher; of these infants, 377 were enrolled in the study and randomly allocated to ART-Def (n=125), The median age of the 377 infants at enrolment was 7·4 weeks; 85% were exposed to drugs for prevention of mother-to-child transmission-most (51%) to a single dose of nevirapine (table 1) . No infant had CDC severe stage B or C clinical disease, median weight-for-age Z score was near normal (−0·7), median CD4% was 35%, and mean viral load was log 5·7 copies per mL. Only 54 infants (14·3%) were breastfed. 2 Median follow-up was 249 weeks (or 4·8 years; 95% CI 3·5-5·9 years). 34 children (9%) were lost to follow-up, having been in the study for a median of 67 weeks (IQR 29-124). The proportion of total follow-up time on ART was 81% in the ART-Def group, 70% in the ART-40W group, and 69% in the ART-96W group (fi gure 2). The median time from randomisation to ART initiation in ART-Def was 20 weeks (95% CI [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] . Median time to starting of continuous ART after interruption was 33 weeks (95% CI 26-45) for ART-40W and 70 weeks (35-109) for ART-96W. This period was estimated by time from randomisation to starting of continuous ART minus 40 weeks (for ART-40W) and minus 96 weeks (for ART-96W) to adjust for length of early ART; thus the diff erence between ART-96W and ART-40W was 37 (−11 to 85) weeks (p=0·13, fi gure 2). Seven children switched to second-line therapy: three in ART-Def, three in ART-40W, and one in ART-96W.
32 primary endpoint events occurred in ART-40W and 26 in ART-96W, compared with 48 in ART-Def (table 2) .
Death comprised nearly half of the primary endpoints in ART-Def versus about a third in the early ART groups. Immunological and clinical failures on ART were similar across the groups, but virological failure was more common in ART-Def than in early ART. Relative to ARTDef, the HR for death or failure of fi rst-line therapy in ART-40W was 0·59 (95% CI 0·38-0·93, p=0·023), and in ART-96W was 0·47 (0·29-0·76, p=0·002). The HR for time to primary endpoint in ART-96W relative to ART-40W was 0·79 (0·47-1·32, p=0·36).
23 deaths (18%) occurred in ART-Def and 11 (9%) in each of ART-40W and ART-96W (table 3) . Relative to ART-Def, the HR for death was 0·40 (95% CI 0·19-0·85, p=0·02) in ART-40W and 0·45 (0·22-0·91, p=0·03) in ART-96W.
Over the entire follow-up period, relative to ART-Def, the HR for clinical disease progression events was 0·53 (95% CI 0·34-0·82, p=0·005) in ART-40W and 0·42 (0·26-0·67, p=0·0003) in ART-96W (table 3) . The cumulative probability of clinical disease progression or death by 3·5 years was 41% in the ART-Def group, 28% in the ART-40W group, and 21% in the ART-96W group. Relative to ART-Def, the diff erence for ART-40W was 13% (95% CI 1-25, p=0·03) and that for ART-96W was 20% (9-31, p=0·0006).
The number of children who died or experienced HIV events associated with end-organ damage was 34 (27%) in the ART-Def group, 18 (14%) in the ART-40W group, and 13 (10%) in the ART-96W group. Relative to ART-Def, the HR for death or HIV events associated with endorgan damage was 0·48 (95% CI 0·27-0·84, p=0·011) in ART-40W and 0·34 (0·18-0·64, p=0·0009) in ART-96W. The hospital admission rate in ART-Def was double that in the early time-limited ART groups (p<0·0001, table 3).
By the end of the trial, 24 children (19%) in ART-40W and 40 (32%) in ART-96W had not started continuous ART. Nevertheless, the median CD4% was 30% or higher in all groups and anthropometric data were well within population standards and similar in all groups (table 3) .
Of 331 children on ART for at least 24 weeks who had their viral load measured at the last study visit, similar proportions had HIV RNA of less than 400 copies per mL (table 3) . Of 32 children with viral load greater than 1000 copies per mL (fi ve in ART-Def, 14 in ART-40W, and 13 in ART-96W), resistance testing was undertaken in 31. Only two children had protease inhibitor mutations that were not present at baseline (one each in ART-Def and ART-40W; both Val82Ala) and seven (23%) had Met184Val mutations (one ART-Def, fi ve ART-40W, and one ART-96W). No thymidine-associated mutations and no diff erences between randomised groups for any resistance were recorded.
Few grade 3 or 4 clinical or laboratory events were thought to be ART-related. Although clinical event rates were signifi cantly higher in the ART-Def group (p<0·0001), rates of laboratory events (particularly those thought to be ART related) were similar and low in all 
Discussion
The results of the completed CHER trial show that early time-limited ART in young infants is better than deferred ART over an extended period. During planned interruption after primary therapy, the rapid disease course noted with deferred ART 2 was not recorded, perhaps because the children given early time-limited ART were older when ART was discontinued than were those who had not started ART in the ART-Def group. Another explanation is that initiation of ART shortly after infection limits both the reservoir of persisting HIV and viral diversity and preserves the immune response. 16, 17 Paradoxically, the proportion of time spent on ART was highest in the deferred treatment group, which also had the highest number of deaths, clinical events, and admissions to hospital. Thus, from a health system perspective, early time-limited ART was less costly than deferred ART, which supports the cost analysis based on early CHER trial data. 18 Three adult studies addressing early ART with subsequent treatment interruption showed a benefi t in higher CD4 count and lower viral set point, but unlike the CHER trial, did not show clinical benefi t (panel). [22] [23] [24] Of note, no randomised trials in adults or children have compared early continuous ART with early time-limited ART. We recorded marginally better outcomes with longer primary therapy. A longer period than that used in our trial might have plausibly sustained better long-term outcomes after interruption. However, the comparative benefi t of early therapy could also be fi nite, and longer periods of primary therapy might not allow increasingly longer periods off ART.
Treatment interruption after primary infection seems to be very diff erent to such interruption in chronic, well established HIV infection, which in adults is associated with increased morbidity and mortality. 25 Unexpectedly, non-infectious renal, cardiovascular, and hepatic disease can contribute to poor outcomes during treatment interruption in adults. 25 No excess non-infectious morbidity was noted during treatment. Two pilot randomised trials, PENTA 11 in Europe 26 and the Optimizing Paediatric HIV-1 Therapy 03 (OPH03) study in Kenya, 20 have assessed CD4-driven planned treatment interruptions in older children with HIV infection. Neither study reported signifi cant morbidity. 20, 26 Unlike in adults, greater CD4 recovery after interruption is possible in children. 26 In the smaller Kenyan study, children could not interrupt therapy beyond 3 months without reaching CD4 criteria for ART re-initiation. These data suggest that interruption after ART that is initiated later in infancy than in the CHER trial is unlikely to succeed, at least in Africa.
The neurodevelopmental consequences of deferral or interruption of ART need consideration. HIV encephalopathy was more common in the ART-Def group compared with ART-40W and ART-96W in CHER, which is similar to the results of the CHER infancy neurodevelopmental substudy in Cape Town. 27 Of note, no neurodevelopmental consequences were reported in longterm follow-up of PENTA 11 28 or among children chronically infected with HIV on deferred ART in the Paediatric Randomised Early versus Deferred Initiation in Cambodia and Thailand (PREDICT) trial. 29 However, children in both trials infected with HIV functioned worse than did their uninfected peers, suggesting that early ART initiation, as in the CHER trial, could be neuroprotective. Long-term results of detailed neurodevelopmental testing are awaited from CHER substudies.
An important fi nding in CHER is the excellent longterm outcome despite interruption with use of a protease inhibitor-based fi rst-line ART regimen. Very few chil dren (seven in total) switched to second-line
Panel: Research in context
Systematic review
We searched PubMed and Scopus for randomised clinical trials that compared early limited or short course antiretroviral therapy during primary, early, or acute HIV infection. There were no restrictions for age or language. We included additional studies known to the authors. In a small pilot study from Durban, South Africa, infants starting immediate ART (n=43) had fewer minor illness episodes than did those treated with deferred ART (n=20; p=0·003), and were less likely to be admitted to hospital (p=0·09) during a 1-year period, but with no diff erence in mortality. Data for planned treatment interruption were not presented. 19 In the Optimizing Paediatric HIV-1 Therapy 03 (OPH03) study in Kenya, infants started ART at a median age of 5 months. Treatment was interrupted after 24 months, with 14 of 21 infants reaching CD4 restart criteria within 3 months. 20 The children with HIV early antiretroviral (CHER) trial is the only large randomised study of young infants identifi ed shortly after birth at a median of 7 weeks of age. Clinical endpoints, mainly death, occurred early, and a signifi cantly higher number occurred in the deferred treatment group, despite a longer period on continuous ART.
Studies in adults are limited by an inability to accurately identify the timing of infection. Only one adult study had clinical endpoints. Here, zidovudine given for 6 months was associated with fewer opportunistic infections than was a deferred strategy. 21 Two small studies, the Setpoint (ACTG A5217) and Primo-SHM trials, showed a lower average viral load after early time-limited ART than with deferred ART. 22, 23 The Short Pulse Anti-Retroviral Therapy at Sero-conversion (SPARTAC) trial, which had a similar design to the CHER trial, showed substantially lower viral load and higher CD4 trajectories after early time-limited ART for 48 weeks.
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Interpretation
The CHER trial, whose composite primary endpoint was clinical, immunological, and virological, establishes the feasibility and safety of early time-limited ART in asymptomatic young infants infected with HIV without severe CD4+ T-cell depletion. Although existing data are still insuffi cient to universally recommend early time-limited ART for infants, this strategy was safe and superior to deferral of ART initiation, which should actually start as soon as possible after birth. The trial also confi rms the durability and absence of toxicity of the fi rst-line regimen consisting of lopinavir-ritonavir, lamivudine, and zidovudine.
ART. Viral suppression rates were excellent after nearly 5 years. As in the PENPACT1 trial, 30 protease inhibitorbased ART with ongoing viral replication protects against developing thymidine-associated mutations as opposed to non-nucleoside reverse transcriptase-based ART. The same protease inhibitor-based regimen was more eff ective than was nevirapine-based fi rst-line therapy in P1060 at 24 weeks, irrespective of previous ART exposure for prevention of mother-to-child transmission. 31 Cumula tively, both studies reported few drugrelated adverse events, which emphasises the safety of this regimen in children.
The CHER trial has some limitations. First, since screening began only after 4 weeks of age, we cannot comment on in-utero versus intrapartum infections. Second, we did not include an early continuous ART group or one given more prolonged primary therapy. Third, the trial was insuffi ciently powered to detect diff erences between the ART-40W and ART-96W groups, which would have needed a much larger sample size.
An important consideration is the extent to which early time-limited ART would be feasible in resource-poor settings, because of the need for close clinical and CD4 monitoring. In many settings with a high HIV prevalence, great heterogeneity exists in resource availability. For example, in South Africa, viral loads and CD4 counts are readily available, as is the case in a few centres of excellence in many other African countries. Point-of-care CD4 and viral load tests will hopefully become available in the near future. Finally, caregivers might stop ART, and drug stock-outs are not uncommon. To understand the risks and benefi ts associated with treatment interruption at diff erent ages is therefore important.
The CHER trial supports the concept and feasibility of early time-limited primary ART for infants without CD4 depletion, provided that close clinical and CD4 monitoring is available. The seemingly better outcome with treatment for 96 weeks rather than 40 weeks favours longer primary treatment and opens the way for ART interruption to assess for sterilising or functional cure after very early ART. 16, 17 More crucially, with ART coverage in children at only 28% in 2011, our results emphasise the urgency of increasing early diagnosis and ART initiation in young infants, extending to entry points other than prevention of mother-to-child transmission programmes. 32 Finally, the CHER trial results support the durability and robustness of lopinavirritonavir-based fi rst-line ART for infants, which should encourage the development of cheaper, more palatable formulations for infants. Further studies of immunological responses to early ART and the virological and immunological consequences of ART interruption are ongoing with use of stored samples, and will contribute to the cure agenda by increasing our understanding of HIV pathogenesis in young, vertically infected HIVpositive infants.
